dc.creatorFunes, Samanta Celeste
dc.creatorde Lara, Amaranta Manrique
dc.creatorAltamirano Lagos, María J.
dc.creatorMackern Oberti, Juan Pablo
dc.creatorEscobar Vera, Jorge
dc.creatorKalergis, Alexis M.
dc.date.accessioned2020-12-17T17:16:45Z
dc.date.accessioned2022-10-15T09:45:07Z
dc.date.available2020-12-17T17:16:45Z
dc.date.available2022-10-15T09:45:07Z
dc.date.created2020-12-17T17:16:45Z
dc.date.issued2019-04
dc.identifierFunes, Samanta Celeste; de Lara, Amaranta Manrique; Altamirano Lagos, María J.; Mackern Oberti, Juan Pablo; Escobar Vera, Jorge; et al.; Immune checkpoints and the regulation of tolerogenicity in dendritic cells: Implications for autoimmunity and immunotherapy; Elsevier Science; Autoimmunity Reviews; 18; 4; 4-2019; 359-368
dc.identifier1568-9972
dc.identifierhttp://hdl.handle.net/11336/120787
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4371959
dc.description.abstractThe immune system is responsible for defending the host from a large variety of potential pathogens, while simultaneously avoiding immune reactivity towards self-components. Self-tolerance has to be tightly maintained throughout several central and peripheral processes; immune checkpoints are imperative for regulating the immunity/tolerance balance. Dendritic cells (DCs) are specialized cells that capture antigens, and either activate or inhibit antigen-specific T cells. Therefore, they play a key role at inducing and maintaining immune tolerance. DCs that suppress the immune response have been called tolerogenic dendritic cells (tolDCs). Given their potential as a therapy to prevent transplant rejection and autoimmune damage, several strategies are under development to generate tolDCs, in order to avoid activation and expansion of self-reactive T cells. In this article, we summarize the current knowledge relative to the main features of tolDCs, their mechanisms of action and their therapeutic use for autoimmune diseases. Based on the literature reviewed, autologous antigen-specific tolDCs might constitute a promising strategy to suppress autoreactive T cells and reduce detrimental inflammatory processes.
dc.languageeng
dc.publisherElsevier Science
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S1568997219300321
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.autrev.2019.02.006
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAUTOIMMUNITY
dc.subjectIMMUNE CHECKPOINTS
dc.subjectIMMUNOTHERAPY
dc.subjectTOLERANCE
dc.subjectTOLEROGENIC DENDRITIC CELLS
dc.titleImmune checkpoints and the regulation of tolerogenicity in dendritic cells: Implications for autoimmunity and immunotherapy
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución